Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547783 | 1.00 | THRB (0.33) | THRBS1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL6548079 | 0.91 | HTT (0.31) | THRBS1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL6548076 | 0.91 | HTT (0.31) | THRBS1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL6548640 | 0.90 | HTT (0.32) | HTTMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL6548638 | 0.90 | HTT (0.32) | HTTMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL6549664 | 0.90 | THRB (0.33) | THRBS1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL6549669 | 0.90 | THRB (0.33) | THRBS1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL6549963 | 0.90 | THRB (0.33) | THRBS1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL6549967 | 0.90 | THRB (0.33) | THRBS1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL6548480 | 0.90 | HTT (0.30) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975586-B1 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6448444-B2 | INSECTICIDES, MITICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6437184-B1 | INSECTICIDES, ACARICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | CBR3, CBR1, NOX3 | THRB 1780/4885S1PR2 2362/4885S1PR1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.